Dr. Lamanna reviews updated long-term data in the frontline chronic lymphocytic leukemia (CLL) setting from phase 3 trials of Bruton tyrosine kinase (BTK) inhibitors that will be presented at the American Society of Hematology (ASH) 2023 annual meeting.

She highlights an analysis across three frontline ibrutinib (Imbruvica) trials (RESONATE, ILLUMINATE, E1912) showing over 70% progression-free survival and overall survival probability at 8 years of follow-up with continuous ibrutinib treatment.

Updated data from the phase 3 Elevate TN study will also be presented showing the progression-free survival benefit of acalabrutinib plus obinutuzumab over acalabrutinib monotherapy maintained over longer-term follow-up. This is one of few studies suggesting added benefit from combining a CD20 antibody with a BTK inhibitor.

Finally, longer-term data from the SEQUOIA trial demonstrates the progression-free survival advantage of zanubrutinib over bendamustine plus rituximab still persists. This benefit is seen even in patients with traditionally poorer prognostic factors like 11q deletion, trisomy 12, unmutated IGHV status, and complex karyotype.

Overall, Dr. Lamanna states these BTK inhibitor trials in the frontline CLL setting continue to show durable efficacy improvements over chemoimmunotherapy regimens.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.